Poor adherence to parenteral osteoporosis therapies during COVID-19 pandemic

Arch Osteoporos. 2021 Feb 26;16(1):46. doi: 10.1007/s11657-021-00904-x.

Roland Kocijan^{1

2

3}, Martina Behanova⁴, Berthold Reichardt⁵, Judith Haschka^{4

6}, Annemarie Kocijan⁷, Jochen Zwerina^{4

6}

¹ Ludwig Boltzmann Institute of Osteology at Hanusch Hospital of OEGK and AUVA Trauma Center Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria. roland.kocijan@osteologie.lbg.ac.at.
² 1st Medical Department, Hanusch Hospital Vienna, Vienna, Austria. roland.kocijan@osteologie.lbg.ac.at.
³ Medical Faculty of Bone Diseases, Sigmund Freud University, Vienna, Austria. roland.kocijan@osteologie.lbg.ac.at.
⁴ Ludwig Boltzmann Institute of Osteology at Hanusch Hospital of OEGK and AUVA Trauma Center Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria.
⁵ Austrian Social Health Insurance Fund, Österreichische Gesundheitskasse, Eisenstadt, Austria.
⁶ 1st Medical Department, Hanusch Hospital Vienna, Vienna, Austria.
⁷ Optimal Essen e.U, Vienna, Austria.

No abstract available

Keywords: COVID-19; Denosumab; Ibandronic acid; Osteoporosis; Zoledronic acid.

Publication types